The DOI matches its Crossref record; 155 of the 156 references it cites were found in a registry or an index.
Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms
Open accessAbstract
Exercise remains a key component of nonalcoholic fatty liver disease (NAFLD) treatment. The mechanisms that underpin improvements in NAFLD remain the focus of much exploration in our attempt to better understand how exercise benefits patients with NAFLD. In this review, we summarize the available scientific literature in terms of mechanistic studies which explore the role of exercise training in modulating fatty acid metabolism, reducing hepatic inflammation, and improving liver fibrosis. This review highlights that beyond simple energy expenditure, the activation of key receptors and pathways may influence the degree of NAFLD-related improvements with some pathways being sensitive to exercise type, intensity, and volume. Importantly, each therapeutic target of exercise training in this review is also the focus of previous or ongoing drug development studies in patients with nonalcoholic steatohepatitis (NASH), and even when a regulatory-agency-approved drug comes to market, exercise will likely remain an integral component in the clinical management of patients with NAFLD and NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aerobic exercise improves key pathophysiologic mechanisms in MASH by enhancing insulin sensitivity, reducing hepatic fat accumulation, increasing mitochondrial fatty acid oxidation, and modulating pro- and anti-inflammatory cytokines independent of weight loss [33].”
From Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hepatic Glucagon Action Is Essential for Exercise-Induced Reversal of Mouse Fatty Liver
Berglund, E. D., Lustig, D. G., Baheza, R. A., Hasenour, C. M., Lee, R. S., Donahue, E. P., Lynes, S. E., Swift, L. L., Charron, M. J., Damon, B. M., et al. (2011) · Diabetes · doi:10.2337/db11-0455 · Cited by 47 · cited 1×
“PPAR-γ is heavily involved in glucagon signaling and insulin sensitivity and, thus, is closely related to adiposity-related disorders [94,95].”
BackgroundRetractedCintra, D. E., Ropelle, E. R., Vitto, M. F., Luciano, T. F., Souza, D. R., Engelmann, J., Marques, S. D. O., Lira, F. S., Pinho, R. A., Pauli, J. R., et al. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.08.002 · Cited by 35
Retracted(1985) · Europe PMC (PubMed Central) · Cited by 9,143
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“GLP-1 has recently emerged at the forefront of drug development in NASH given the recent promising results of early-phase studies using both semaglutide [11] as well as liraglutide [53] and the fact that several GLP-1 receptor agonists are regulatory-agency-approved for the medical treatment of overweight and obesity…”
BackgroundOxidative Stress: Harms and Benefits for Human Health
Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D., & Bitto, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/8416763 · Cited by 4,837
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“One such hormone is GLP-1, an incretin, which helps to regulate satiety and lipid metabolism in both the fasting and glucose-stimulated states [52].”
BackgroundYounossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383 · cited 1×
“Upwards of 30% of the world’s population has nonalcoholic fatty liver disease (NAFLD) [1].”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“The PPAR pathway remains one of many targets for drug discovery of anti-steatogenic medications, where late-phase studies have demonstrated PPAR-γ agonists, such as pioglitazone [96], and dual PPAR-α/γ agonists, such as saroglitazar [15], improve insulin resistance and lipid metabolism through regulation of fatty acid…”
BackgroundRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 1×
“However, most patients with NAFLD do not meet recommended amounts of weekly physical activity [2], and no one optimal diet has been established, although a Mediterranean-informed diet appears to hold the most promise and is recommended by several leading gastroenterology and hepatology societies [3,4].”
BackgroundArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · cited 1×
“GLP-1 has recently emerged at the forefront of drug development in NASH given the recent promising results of early-phase studies using both semaglutide [11] as well as liraglutide [53] and the fact that several GLP-1 receptor agonists are regulatory-agency-approved for the medical treatment of overweight and obesity…”
Background
Research works printed but not linked: 1
- Noureddin, 2022, HU6 reduces liver fat in subjects with high BMI NAFLD: Top-line results from a phase 2a trial, Hepatology, 76, S94
Cited by
Keating, S. E., Sabag, A., Hallsworth, K., Hickman, I. J., Macdonald, G. A., Stine, J. G., George, J., & Johnson, N. A. (2023) · Sports Medicine · doi:10.1007/s40279-023-01918-w · Cited by 119
“The mechanisms by which exercise modulates hepatic steatosis have been detailed elsewhere [14, 44–46].”
Self-citationAltered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Radosavljević, T. S., Branković, M., Samardžić, J., Djuretić, J., Vukićević, D., Vučević, D. B., & Jakovljevic, V. L. (2024) · Antioxidants · doi:10.3390/antiox13080906 · Cited by 102
“Exercise has been shown to reduce fat accumulation in the liver by enhancing fatty acid oxidation and inhibiting lipogenesis, primarily through the activation of the AMP-activated protein kinase (AMPK) pathway [62].”
The Role of Exercise in Steatotic Liver Diseases: An Updated Perspective
Razzak, I. A., Fares, A., Stine, J. G., & Trivedi, H. D. (2024) · Liver International · doi:10.1111/liv.16220 · Cited by 61
“In their review, Heinle et al. identify 10 distinct mechanisms or cellular targets through which exercise exerts a therapeutic effect on MASLD [32].”
Self-citationKeating, S. E., Chawla, Y. K., De, A., & George, E. S. (2024) · Hepatology International · doi:10.1007/s12072-024-10663-9 · Cited by 49
“Detailed mechanisms underlying the benefits of exercise on reductions in hepatic steatosis and inflammation are reported elsewhere [17, 57, 69–71]; and summarised in Fig.”
BackgroundSelf-citationAli, H., Shahzil, M., Moond, V., Shahzad, M., Thandavaram, A., Sehar, A., Waseem, H., Siddiqui, T. A., Dahiya, D. S., Patel, P., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010061 · Cited by 44
“[17,18].”
Background
Metadata
- Authors
- Heinle, J. W., DiJoseph, K., Sabag, A., Oh, S., Kimball, S. R., Keating, S., & Stine, J. G.
- Affiliations
- Pennsylvania State University (US)
- The University of Sydney (AU)
- R Professional University Of Rehabilitation (JP)
- The University of Queensland (AU)
- Corresponding author
- Stine, Jonathan G.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2023-05-24
- Volume
- 15
- Issue
- 11
- Pages
- 2452
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC10255270
- OpenAlex
- W4378229185
- Cited by
- 26
- References
- 156
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 9 · 2023: 2
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (K23DK131290)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Physiology (medical) › Exercise and Physiological Responses
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
- Keywords
- exercise training, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, fatty acid metabolism, liver inflammation, liver fibrosis, energy expenditure, exercise intensity and volume, drug development
- MeSH terms
- Humans, Liver, Liver Cirrhosis, Exercise, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms. https://app.cochat.ai/papers/10.3390/nu15112452
- The paper
- Heinle, J. W., DiJoseph, K., Sabag, A., Oh, S., Kimball, S. R., Keating, S., & Stine, J. G. (2023). Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms. Nutrients. https://doi.org/10.3390/nu15112452
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.